BioMerieux Comprehensive Income 2017-2024 | BMXMF
BioMerieux comprehensive income from 2017 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- BioMerieux comprehensive income for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- BioMerieux comprehensive income for 2024 was $0B, a 0% decline from 2023.
- BioMerieux comprehensive income for 2023 was $0B, a 0% decline from 2022.
- BioMerieux comprehensive income for 2022 was $0B, a 0% decline from 2021.
| BioMerieux Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $0 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $0 |
| BioMerieux Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.263B | $4.307B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $143.728B | 26.96 |
| Elevance Health (ELV) | United States | $94.145B | 12.15 |
| CVS Health (CVS) | United States | $81.986B | 10.19 |
| Cencora (COR) | United States | $53.983B | 18.77 |
| Natera (NTRA) | United States | $21.477B | 0.00 |
| DiDi Global (DIDIY) | China | $21.462B | 32.57 |
| Solventum (SOLV) | United States | $12.941B | 13.70 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.036B | 0.00 |
| Revvity (RVTY) | United States | $11.610B | 19.98 |
| Doximity (DOCS) | United States | $11.396B | 59.26 |
| ICON (ICLR) | Ireland | $11.324B | 10.53 |
| CochLear (CHEOY) | Australia | $11.195B | 0.00 |
| Viatris (VTRS) | United States | $10.516B | 3.61 |
| Medpace Holdings (MEDP) | United States | $9.017B | 23.95 |
| Avantor (AVTR) | United States | $8.859B | 12.87 |
| HealthEquity (HQY) | United States | $8.361B | 41.13 |
| Sonic Healthcare (SKHHY) | Australia | $8.215B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.027B | 13.77 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| Bausch + Lomb (BLCO) | Canada | $4.202B | 24.77 |
| BrightSpring Health Services (BTSG) | United States | $3.894B | 36.05 |
| Sotera Health (SHC) | United States | $3.832B | 21.77 |
| Surgery Partners (SGRY) | United States | $2.982B | 38.77 |
| Alignment Healthcare (ALHC) | United States | $2.952B | 0.00 |
| Concentras Parent (CON) | United States | $2.771B | 16.01 |
| Organon (OGN) | United States | $2.264B | 2.41 |
| Ardent Health Partners (ARDT) | United States | $2.121B | 9.04 |
| Premier (PINC) | United States | $2.101B | 14.38 |
| Progyny (PGNY) | United States | $1.886B | 41.51 |
| PACS (PACS) | United States | $1.698B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.683B | 64.83 |
| GoodRx Holdings (GDRX) | United States | $1.669B | 31.07 |
| Teladoc Health (TDOC) | United States | $1.289B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.234B | 9.39 |
| Agilon Health (AGL) | United States | $1.229B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.000B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| CareDx (CDNA) | United States | $0.911B | 14.23 |
| AMN Healthcare Services Inc (AMN) | United States | $0.866B | 8.11 |
| Embecta (EMBC) | United States | $0.725B | 4.89 |
| QDM (QDMI) | Hong Kong, SAR China | $0.690B | 0.00 |
| Nutex Health (NUTX) | United States | $0.689B | 13.50 |
| Enhabit (EHAB) | United States | $0.530B | 43.58 |
| InnovAge Holding (INNV) | United States | $0.513B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.513B | 13.59 |
| Sonida Senior Living (SNDA) | United States | $0.512B | 0.00 |
| LifeMD (LFMD) | United States | $0.389B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.363B | 0.00 |
| SBC Medicals (SBC) | United States | $0.359B | 0.00 |
| Beauty Health (SKIN) | United States | $0.220B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.202B | 0.00 |
| Oncology Institute (TOI) | United States | $0.193B | 0.00 |
| DocGo (DCGO) | United States | $0.147B | 24.08 |
| Sera Prognostics (SERA) | United States | $0.087B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.087B | 0.00 |
| KindlyMD (KDLY) | United States | $0.082B | 0.00 |
| OncoCyte (OCX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.076B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.054B | 0.00 |
| Biodesix (BDSX) | United States | $0.053B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.031B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| ModivCare (MODV) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.011B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |